India, June 11 -- UCB (UCB) announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and ankylosing spondylitits (AS).
BIMZELX, a dual inhibitor of IL-17A and IL-17F, demonstrated sustained control of inflammation and deep efficacy in patients living with psoriatic arthritis and active axial spondyloarthritis, chronic inflammatory diseases with considerable impact on physical and emotional wellbeing.
In patients with active PsA, regardless of prior treatment experience, resu...